Cargando…
The evolving role of DNA damage response in overcoming therapeutic resistance in ovarian cancer
Epithelial ovarian cancer (EOC) is treated in the first-line setting with combined platinum and taxane chemotherapy, often followed by a maintenance poly (ADP-ribose) polymerase inhibitor (PARPi). Responses to first-line treatment are frequent. For many patients, however, responses are suboptimal or...
Autores principales: | Bouberhan, Sara, Bar-Peled, Liron, Matoba, Yusuke, Mazina, Varvara, Philp, Lauren, Rueda, Bo R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
OAE Publishing Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344720/ https://www.ncbi.nlm.nih.gov/pubmed/37457127 http://dx.doi.org/10.20517/cdr.2022.146 |
Ejemplares similares
-
Exploiting the Prevalence of Homologous Recombination Deficiencies in High-Grade Serous Ovarian Cancer
por: Bouberhan, Sara, et al.
Publicado: (2020) -
T7 replisome directly overcomes DNA damage
por: Sun, Bo, et al.
Publicado: (2015) -
Long noncoding RNAs as therapeutic targets to overcome chemoresistance in ovarian cancer
por: Chen, Linjiao, et al.
Publicado: (2022) -
Evolving Drug Delivery Strategies to Overcome the Blood Brain Barrier
por: Hersh, David S., et al.
Publicado: (2016) -
Overcoming Pluripotent Stem Cell Dependence on the Repair of Endogenous DNA Damage
por: Chlon, Timothy M., et al.
Publicado: (2016)